Activated Charcoal Ammi Visnaga Fruit Carbo Animal
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Ammi Visnaga Fruit Carbo Animal
- Multi-Ingredient Combination (12 Components): Insufficient Data for Repurposing Evaluation
Multi-Ingredient Combination (12 Components): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This evidence pack describes a complex 12-component combination product (including Activated Charcoal, Ammi Visnaga Fruit, Nitric Acid, Palladium, Platinum, Potassium Arsenite Anhydrous, and others) whose composition resembles a homeopathic or traditional compound formula. The TxGNN model returned no predicted new indications for this combination, and no original indications are on record. With zero clinical trials, zero publications, and no US market authorization, the current evidence base is insufficient to support any repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this compound, so a standard mechanistic rationale cannot be established.
Currently, detailed mechanism of action data is not available. This product is a 12-ingredient combination that includes both conventional compounds (Activated Charcoal, Selenium, Sarsaparilla) and homeopathic-grade substances (Carbo Animalis, Nitricum Acidum, Palladium, Platinum, Potassium Arsenite Anhydrous, Quinine Arsenate). The profile is consistent with a homeopathic or anthroposophic compound formula, a category not well-represented in TxGNN’s knowledge graph, which likely explains why no disease node could be matched and no prediction was returned.
Without a DrugBank ID, no machine-readable pharmacological profile exists. Individually, some components carry recognized pharmacological activity — Ammi Visnaga contains khellin (a calcium-channel modulator historically associated with bronchodilation and antispasmodic effects), and Selenium is an established trace element with antioxidant roles — but their contributions in this combination at unknown dilutions cannot be assessed with current data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
This product has no US NDA, ANDA, or BLA on record, and is not found in the Taiwan TFDA license database. No authorization table can be generated.
Safety Considerations
Please refer to the package insert for safety information.
Attention: This combination contains ingredients with known toxicity concerns at pharmaceutical-grade doses — specifically Potassium Arsenite Anhydrous (inorganic arsenic), Nitric Acid, Daphne Mezereum Bark (a known vesicant and cytotoxin), and heavy metals (Palladium, Platinum). If this product is being evaluated for any clinical or research use, a dedicated toxicological and genotoxicity assessment is required before proceeding.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model generated no predicted indications, the product has no regulatory authorization in any recorded jurisdiction, and critical data including MOA, original indication, and safety profile are all absent. The presence of multiple potentially toxic components (inorganic arsenite, mezereum bark, heavy metals) further elevates the data-gap risk before any clinical hypothesis can be evaluated.
To proceed, the following is needed:
- Identity clarification: Confirm whether this is a licensed homeopathic product (e.g., Sanum, Heel, or similar brand) with a known product name that can be queried individually
- Component-level DrugBank mapping: Query each of the 12 ingredients separately to retrieve individual DrugBank IDs and MOA data
- Regulatory status check: Search FDA Homeopathic Drug Products database and EU HMPC monographs for any of the individual components
- Toxicology assessment: Obtain dose/dilution information for Potassium Arsenite Anhydrous, Daphne Mezereum Bark, Nitric Acid, Palladium, and Platinum before any repurposing hypothesis is formed
- Re-run TxGNN per component: If individual DrugBank IDs are obtained for the active pharmacological components, re-run the TxGNN pipeline per ingredient to surface any disease associations
- TFDA package insert retrieval: Download and parse the package insert PDF (DG001 remediation) to fill the blocking safety data gap
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.